2010 discharge: IMI Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines

PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2010, as part of the 2010 discharge procedure.

Analysis of the accounts of the Innovative Medicines Initiative Joint Undertaking (IMI).

CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2010 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the Innovative Medicines Initiative Joint Undertaking (IMI).

In 2010, the tasks and budget of this agency were as follows:

• description of the tasks of the Joint Undertaking: the IMI Joint undertaking, which is located in Brussels, was set up in 2007 by Council Regulation (EC) No 73/2008 for a period of 10 years. Its main task is to improve significantly the efficiency and effectiveness of the drug development process; 
• budget of the Joint Undertaking for the 2010 financial year: the maximum EU contribution to the IMI Joint Undertaking to cover running costs and research activities is EUR 1 billion to be paid from the budget of the Seventh Research Framework Programme. In 2010, the EU's contribution amounted to EUR 107 million in commitment appropriations and EUR 29 million in payment appropriations.

The complete version of the Agency's final accounts may be found at the following address: http://www.imi.europa.eu/content/budget-0